Therapy: SGLT inhibition in T1DM — definite benefit with manageable risk

Nature Reviews Endocrinology, Published online: 27 October 2017; doi:10.1038/nrendo.2017.139

Two phase III trials using the selective SGLT2 inhibitor dapagliflozin or the dual SGLT2/SGLT1 inhibitor sotagliflozin in patients with type 1 diabetes mellitus show similar clinical benefit (reduction of HbA_1c, body weight, blood pressure and insulin dose). The risk of hypoglycaemia and diabetic ketoacidosis with these inhibitors can be managed by careful adjustment of insulin therapy.

中文翻译：

---

治疗：T1DM中的SGLT抑制-具有可控风险的明确收益

治疗：T1DM中的SGLT抑制-具有可控风险的明确收益

Nature Reviews Endocrinology，在线发表：2017年10月27日；doi：10.1038 / nrendo.2017.139

在1型糖尿病患者中使用选择性SGLT2抑制剂dapagliflozin或双重SGLT2 / SGLT1抑制剂sotagliflozin进行的两项III期试验显示出相似的临床获益（降低HbA _1c，体重，血压和胰岛素剂量）。这些抑制剂引起的低血糖和糖尿病性酮症酸中毒的风险可以通过仔细调整胰岛素治疗来控制。